Online weight loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index, which ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.

Pharmaceutical manufacturing giant Eli Lilly and Co. is exploring potential economic incentives for a $5.9B biomanufacturing ...

Compounding pharmacies are supposed to stop producing the compounded versions of the popular weight loss medications now that ...

While weight loss medications are usually not covered by insurance, there are other ways to secure a medication without a provider. There are 13 states whose Medicaid programs allow for GLP-1 drugs to ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

Eli Lilly plans to pursue approval for its new GLP-1 pill by the end of this year. Fact checked by Nick Blackmer A daily pill ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Apnimed will be waiting for the readout from a second Phase III trial before it approaches the FDA with an NDA for the sleep ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...